Pipeline

Therapeutic Focus

We are exploring innovative approaches in immunology where we have the opportunity to make a clinically meaningful difference for patients relative to standard of care.
Therapeutic Focus
Program
indication
preclinical
phase 1
phase 2
phase 3
Izokibep
Hidradenitis Suppurativa *
Psoriatic Arthritis
Axial Spondyloarthritis
Uveitis *
Lonigutamab (anti-IGF-1R)
Thyroid Eye Disease
XLRN-517 (anti-C-KIT)
Chronic Urticaria

*The FDA has previously granted orphan drug status for the treatment of these rare diseases.

Indications

Hidradenitis Suppurativa

Psoriatic Arthritis

Axial Spondyloarthritis

Uveitis

Thyroid Eye Disease

Chronic Urticaria

Hidradenitis suppurativa (HS) is a very painful, lifelong, and recurring skin condition that causes abscesses and scarring 1,2. Areas often affected include the groin and genitals, the armpits, areas around the anus, and below the breasts1,2.

*Izokibep is not yet approved for use in any indication.
News Center

The Latest Company
Announcements and Resources